Britain and America have forged a important trade agreement that will ensure no levies on British pharmaceutical exports entering the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to increase funding on pharmaceuticals through the public health system. This commitment secures that duties on these vital exports will remain at zero for a duration of the next three years.
This agreement comes after previous warnings to dramatically increase duties on branded drug imports, with increases discussed up to double the cost.
"This agreement between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. medicine commerce," a statement noted.
Commercial Impact
Medicines constitute one of the UK's most significant export categories to the America, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Trade data reveal that in the year leading up to last September, the UK shipped medicines valued at billions to the US. This amount represented 17.4% of total UK exports in that span.
"This guarantee safeguards jobs, boosts investment and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The agreement involves several notable pledges from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded twenty percent.
Industry Background
This agreement takes place against a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were intensified by assertions that American customers were charged a premium for the same drugs than consumers in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been paused or scrapped, while major funding commitments have been announced toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the past decade.
